Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- 37
Summary
- Conditions
- Adult Nasal Type Extranodal NK/T-cell Lymphoma
- Anaplastic Large Cell Lymphoma
- Splenic Marginal Zone Lymphoma
- Recurrent Small Lymphocytic Lymphoma
- Angioimmunoblastic T Cell Lymphoma
- Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
- Recurrent Grade 1 Follicular Lymphoma
- Hepatosplenic T Cell Lymphoma
- Nodal Marginal Zone B-cell Lymphoma
- Small Intestine Lymphoma
- Peripheral T Cell Lymphoma
- Recurrent Grade 3 Follicular Lymphoma
- Post Transplant Lymphoproliferative Disorder
- Recurrent Adult Burkitt Lymphoma
- Recurrent Grade 2 Follicular Lymphoma
- Recurrent Adult Diffuse Large Cell Lymphoma
- Recurrent Adult T-cell Leukemia/Lymphoma
- Recurrent Mycosis Fungoides/Sezary Syndrome
- Waldenstrom Macroglobulinemia
- Recurrent Mantle Cell Lymphoma
- Recurrent Adult Lymphoblastic Lymphoma
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
PRIMARY OBJECTIVES: I. To evaluate the proportion of confirmed response of LBH589 in patients with relapsed or refractory non-Hodgkin lymphoma. SECONDARY OBJECTIVES: I. To describe the toxicities associated with LBH589 in patients with NHL. II. To evaluate overall survival, progression-free survival...
PRIMARY OBJECTIVES: I. To evaluate the proportion of confirmed response of LBH589 in patients with relapsed or refractory non-Hodgkin lymphoma. SECONDARY OBJECTIVES: I. To describe the toxicities associated with LBH589 in patients with NHL. II. To evaluate overall survival, progression-free survival, and duration of response in patients treated with LBH589. TERTIARY OBJECTIVES: I. To evaluate the pharmacokinetics of LBH589. II. To assess the correlation between clinical (toxicity and/or tumor response or activity) effects with the pharmacologic (pharmacokinetic/pharmacodynamic) parameters, and/or biologic (correlative laboratory) results. OUTLINE: Patients receive oral panobinostat 3 times weekly. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up every 6 months for up to 2 years.
Tracking Information
- NCT #
- NCT01261247
- Collaborators
- National Cancer Institute (NCI)
- Investigators
- Study Chair: Patrick Johnston, M.D. Mayo Clinic
Get Well Soon